Overview

A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Status:
RECRUITING

Trial end date:
2025-11-08

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the efficacy of medical cannabis aerosol containing 0.25, 0.5, 1.0 milligrams (mg) delta (Δ)9-tetrahydrocannabinol (THC) inhaled three times a day (TID) compared to placebo via the Fixed-dose Syqe Inhaler on pain intensity at Week 15.

Phase:

PHASE2

Details

Lead Sponsor:

Syqe Medical

Treatments:

Medical Marijuana